STAT

FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Swiss pharma giant Roche won approval from the ...

TG Therapeutics Gains on Positive Data for Subcutaneous Multiple Sclerosis Drug

Shares of TG Therapeutics rose after the company reported positive data for new subcutaneous formulation of a multiple sclerosis treatment. The stock climbed 12%, to $41.21, Wednesday afternoon and is ...
Multiple Sclerosis News Today

CMSC 2026: Trial data show frexalimab benefits lasting 3 years

The benefits of frexalimab in people with relapsing MS have been sustained for up to three years in a clinical trial, data ...
Medical Xpress

FDA approves injectable Ocrevus Zunovo for relapsing, progressive multiple sclerosis

The U.S. Food and Drug Administration has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) as the first and only twice-a-year, 10-minute subcutaneous injection for people with relapsing ...
Healio

FDA approves first twice-a-year, subcutaneous injection for multiple sclerosis

Please provide your email address to receive an email when new articles are posted on . Genentech announced it received FDA approval for Ocrevus Zunovo to treat patients with relapsing and primary ...
Nasdaq

Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis

OCREVUS subcutaneous (SC) injection offers a new, 10-minute administration of OCREVUS with comparable efficacy and safety to intravenous infusion (IV) OCREVUS SC provides an additional treatment ...
Yahoo

US FDA declines to approve Viatris's injection for multiple sclerosis

Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) -The U.S. FDA has declined to approve Viatris and Mapi Pharma's once-a-month injection for treating relapsing forms of ...
Nasdaq

FDA Approves Ocrevus Zunovo™ as the First and Only Twice-a-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis

Ocrevus Zunovo is the first and only twice-a-year, healthcare professional (HCP)-administered approximately 10-minute subcutaneous (SC) injection approved for both these forms of multiple sclerosis, ...
Washington Examiner

Correction: FDA-Multiple Sclerosis Drug story

WASHINGTON (AP) — In a story March 27 about a new multiple sclerosis drug, The Associated Press reported erroneously that Novartis’ drug Gilenya was launched in March 2011. The drug was launched in ...
Benzinga.com

Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion

Roche Holdings AG's (OTC:RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with ...
MarketWatch

Mapi Pharma to Present Efficacy (EDSS) Data from Glatiramer Acetate Depot Long-Acting Injection Studies in Relapsing Forms of Multiple Sclerosis (RMS) and Primary Progressive ...

The MarketWatch News Department was not involved in the creation of this content. NESS ZIONA, Israel, April 16, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical ...
Gizmodo

Brain Injection Stopped Progression of Multiple Sclerosis in Trial of 15 People

Research published this week describes a promising start to using stem cell therapy for multiple sclerosis. In a small Phase I trial, patients who had stem cells directly injected into their brain ...